Clinical Trial News

The HIMALAYA study's 5-year data revealed that the combination of tremelimumab and durvalumab improved overall survival in unresectable hepatocellular carcinoma patients, with a 5-year survival rate of 19.6% compared to 9.4% with sorafenib. This combination, known as STRIDE, showed sustained OS benefits and deeper tumor responses, setting new standards in uHCC treatment.

ESMO Congress 2024 studies show immunotherapy benefits in early-stage cervical and endometrial cancers, particularly in high-risk locally advanced cervical cancer and endometrial dMMR tumors. A novel antibody-drug conjugate targeting claudin 6 shows promising antitumor activity in ovarian and endometrial cancers.

The FDA has cleared Apple's new sleep apnea detection feature for Apple Watch Series 9, Series 10, and Ultra 2. This feature aims to provide a cheaper, simpler alternative to traditional sleep apnea tests, potentially impacting millions of undiagnosed sufferers. The feature analyzes 'breathing disturbances' using an accelerometer and provides monthly notifications if consistent signs of sleep apnea are detected.

FDA approves Eli Lilly’s Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children aged 12+ weighing at least 88 lbs. Ebglyss targets the IL-13 pathway, with 38% achieving clear or almost-clear skin at 16 weeks vs. 12% on placebo. Common AEs include eye and eyelid inflammation, injection site reactions, and shingles.

FDA approves Eli Lilly's Ebglyss (lebrikizumab) for moderate-to-severe atopic dermatitis, offering once-monthly dosing. Ebglyss targets IL-13, providing clear skin in 38% of patients at 16 weeks, compared to 12% with placebo. Common side effects include eye inflammation, injection site reactions, and shingles.

FDA approves Eli Lilly's Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years old who weigh at least 88 lbs and have uncontrolled eczema despite topical treatments. Ebglyss, a 250 mg/2 mL injection, can be used with or without topical corticosteroids, with an initial dose of 500 mg at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16, then monthly maintenance. Studies showed 38% achieved clear or almost clear skin at 16 weeks (vs. 12% placebo), with 77% maintaining results at one year.

AstraZeneca's Imfinzi shows positive results for bladder cancer; Apple receives FDA approval for hearing aid software on earbuds.

Michael, with 16+ years in writing/editing, covers cardiology, radiology, AI, and other healthcare topics.

New research from Philadelphia College of Osteopathic Medicine shows rapid and significant improvements in health-related quality of life among nearly 400 adults using medical marijuana for anxiety or chronic pain, with notable gains in pain levels, social functioning, and emotional well-being.

Evaxion Biotech reports 69% Overall Response Rate in Phase 2 trial of EVX-01, with 15/16 patients showing tumor reduction. 79% of vaccine targets triggered immune response, and a positive correlation was observed between AI-Immunology™ predictions and neoantigen immune response (p=0.00013). EVX-01 holds significant commercial potential for melanoma treatment.